{"a":[{"_":"Gilead, Merck’s phase 3 data back first weekly HIV pill","$":{"href":"/pharma/gilead-merck-phase-3-data-back-first-weekly-hiv-pill","hreflang":"en"}}]}
Phase 3positiveislatravirlenacapavirBiktarvyPositive
AI Analysis
Summary
Gilead and Merck's phase 3 Islend trials confirmed that their once-weekly single-tablet combination of islatravir and lenacapavir achieved comparable HIV viral suppression to daily treatments like Biktarvy, supporting the first weekly HIV pill candidate.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Once-weekly single-tablet combination of islatravir and lenacapavir matched daily treatments like Biktarvy at maintaining HIV viral suppression in phase 3 Islend trials
Importance:8/10
Sentiment:
0.85
HIVphase 3combination therapyonce-weekly dosingclinical trial results
Read the original article
Published by FiercePharma on July 21, 2026 7:44 AM